FMED.US Fidelity Disruptive Medicine ETF
- Total assets
- 30.3M
- Expense ratio
- 0.51%
- Dividend yield
- -
- 1-year return
- +21.24%
- Holdings
- 70
- Since
- 2020
Fund data as reported by the issuer, updated Nov 13, 2026. Total assets are in the fund's base currency.
What does FMED.US invest in?
- Mostly US stocks (95.8%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (98.8%)
- Top 3 holdings: 12.0% of the fund
Asset allocation
- US stocks 95.8%
- Non-US stocks 6.5%
- Cash 0.6%
- Other 0.0%
Top holdings
- Natera Inc 4.01%
- Danaher Corporation 4.01%
- Thermo Fisher Scientific Inc 3.99%
- 10X Genomics Inc 3.78%
- Lifestance Health Group Inc 3.24%
Fidelity Disruptive Medicine ETF performance
Sharpe ratio 0.69- This year
- +21.84%
- 1 year
- +21.24%
- 3 years
- +17.71%
- 5 years
- +0.82%
Volatility 23.3% over 1 year and 17.9% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
FMED.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Fidelity Disruptive Medicine ETF
The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.
Full fund profileFidelity Disruptive Medicine ETF top holdings
33.0% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Natera Inc NTRA.US | Healthcare | United States | 4.01% |
| Danaher Corporation DHR.US | Healthcare | United States | 4.01% |
| Thermo Fisher Scientific Inc TMO.US | Healthcare | United States | 3.99% |
| 10X Genomics Inc TXG.US | Healthcare | United States | 3.78% |
| Lifestance Health Group Inc LFST.US | Healthcare | United States | 3.24% |
| argenx NV ADR ARGX.US | Healthcare | United States | 3.01% |
| Sartorius Stedim Biotech SA DIM.PA | Healthcare | France | 2.98% |
| Illumina Inc ILMN.US | Healthcare | United States | 2.84% |
| Moderna Inc MRNA.US | Healthcare | United States | 2.70% |
| Revolution Medicines Inc RVMD.US | Healthcare | United States | 2.48% |
The 10 largest of 70 holdings.
FMED.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
FMED.US regional exposure
- North America98.8%
- Europe Developed3.2%
- United Kingdom1.6%
- Asia Emerging0.7%
Share of the stocks in the fund.
Company size
Average market cap 19.1B- Mega cap1.0%
- Big cap15.8%
- Medium cap32.8%
- Small cap32.8%
- Micro cap12.2%
Fidelity Disruptive Medicine ETF fund profile
- Fund name
- Fidelity Disruptive Medicine ETF
- Ticker
- FMED.US
- Exchange
- USA Stocks
- Issuer
- Fidelity Investments
- Index tracked
- -
- Category
- Healthcare Equity
- Inception date
- Apr 16, 2020
- Trading currency
- USD
- Expense ratio
- 0.51%
About Fidelity Disruptive Medicine ETF
The fund normally invests at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. The fund is non-diversified.